• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

chronic lymphocytic leukaemia - Articles and news items

Blood cancer study yields disappointing results

Industry news / 19 July 2016 / Niamh Louise Marriott

Gazyvaro did not meet its primary endpoint of significantly reducing the risk of disease worsening or death in people with diffuse large B-cell lymphoma…

Venetoclax shown to be effective in CLL patients who relapse or are refractory

Industry news / 10 June 2016 /

New data show promising results for venetoclax in patients with chronic lymphocytic leukaemia who have relapsed or become refractory (R/R) to treatment…

NICE asks Janssen to put ibrutinib forward for the CDF

Industry news / 1 June 2016 / Victoria White, Digital Content Producer

NICE has asked Janssen to set out a case for including its chronic lymphocytic leukaemia (CLL) drug ibrutinib (Imbruvica) in the Cancer Drugs Fund (CDF)…

EC approves MabThera for chronic lymphocytic leukaemia

Industry news / 31 May 2016 /

The EC has approved the subcutaneous formulation of MabThera for people with previously untreated and relapsed/refractory chronic lymphocytic leukaemia…

EC approves ibrutinib for patients with newly diagnosed CLL

Industry news / 31 May 2016 / Victoria White, Digital Content Producer

The EC has approved Imbruvica (ibrutinib) for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL)…

FDA approves chronic lymphocytic leukaemia drug Venclexta

Industry news / 12 April 2016 / Victoria White, Digital Content Producer

Venclexta is the first FDA-approved treatment that targets the BCL-2 protein, which supports cancer cell growth and is overexpressed in many CLL patients…

FDA grants breakthrough therapy designation to venetoclax combo in CLL

Industry news / 20 January 2016 / Victoria White

Venetoclax is an investigational small molecule designed to selectively bind and inhibit the BCL-2 protein, which plays an important role in a process called apoptosis…

FDA grants Priority Review for venetoclax NDA

Industry news / 12 January 2016 / Victoria White

The NDA for venetoclax is for the treatment of people with chronic lymphocytic leukaemia who have received at least one prior therapy, including those with 17p deletion…

Mutations in CLL suggest potential new uses for existing cancer drugs

Industry news / 7 December 2015 / Victoria White

By mining the DNA of patients with chronic lymphocytic leukaemia (CLL), researchers at Penn Medicine have uncovered 12 mutations that may be targetable using therapies already available for other cancers…

Servier exercises options to acquire worldwide rights to UCART19

Industry news / 19 November 2015 / Victoria White

Earlier this month, Great Ormond Street Hospital (GOSH) reported that UCART19 had been used treat a one-year-old girl who had relapsed acute lymphoblastic leukaemia…

Blood cancer drug trial reveals life-changing results

Industry news / 11 November 2015 / Victoria White

The clinical trial, a first-in-man study, looked at the efficacy of ONO/GS-4059 in the treatment of Chronic Lymphocytic Leukaemia and Non-Hodgkin Lymphoma patients…

Janssen submits application to EMA to expand use of ibrutinib

Industry news / 4 November 2015 / Victoria White

Janssen seeks to broaden the existing marketing authorisation for ibrutinib to include previously untreated patients with chronic lymphocytic leukaemia…

  • Page 1 of 2
  • 1
  • 2
  • >